| pubmed-article:8535642 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8535642 | lifeskim:mentions | umls-concept:C0003873 | lld:lifeskim |
| pubmed-article:8535642 | lifeskim:mentions | umls-concept:C0036078 | lld:lifeskim |
| pubmed-article:8535642 | lifeskim:mentions | umls-concept:C0038710 | lld:lifeskim |
| pubmed-article:8535642 | lifeskim:mentions | umls-concept:C1552018 | lld:lifeskim |
| pubmed-article:8535642 | pubmed:dateCreated | 1996-2-6 | lld:pubmed |
| pubmed-article:8535642 | pubmed:abstractText | Sulphasalazine is cleaved into 5-aminosalicylic acid and sulphapyridine by colonic bacteria. The bulk of evidence favours sulphapyridine rather than 5-aminosalicylic acid as the active moiety (as well as the main producer of side-effects) though a therapeutic action from the 30% of sulphasalazine that is absorbed unaltered also cannot be excluded. | lld:pubmed |
| pubmed-article:8535642 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8535642 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8535642 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:8535642 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8535642 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8535642 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8535642 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8535642 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8535642 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8535642 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8535642 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8535642 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:8535642 | pubmed:issn | 0263-7103 | lld:pubmed |
| pubmed-article:8535642 | pubmed:author | pubmed-author:BirdH AHA | lld:pubmed |
| pubmed-article:8535642 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8535642 | pubmed:volume | 34 Suppl 2 | lld:pubmed |
| pubmed-article:8535642 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8535642 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8535642 | pubmed:pagination | 16-9 | lld:pubmed |
| pubmed-article:8535642 | pubmed:dateRevised | 2005-11-16 | lld:pubmed |
| pubmed-article:8535642 | pubmed:meshHeading | pubmed-meshheading:8535642-... | lld:pubmed |
| pubmed-article:8535642 | pubmed:meshHeading | pubmed-meshheading:8535642-... | lld:pubmed |
| pubmed-article:8535642 | pubmed:meshHeading | pubmed-meshheading:8535642-... | lld:pubmed |
| pubmed-article:8535642 | pubmed:meshHeading | pubmed-meshheading:8535642-... | lld:pubmed |
| pubmed-article:8535642 | pubmed:meshHeading | pubmed-meshheading:8535642-... | lld:pubmed |
| pubmed-article:8535642 | pubmed:meshHeading | pubmed-meshheading:8535642-... | lld:pubmed |
| pubmed-article:8535642 | pubmed:meshHeading | pubmed-meshheading:8535642-... | lld:pubmed |
| pubmed-article:8535642 | pubmed:meshHeading | pubmed-meshheading:8535642-... | lld:pubmed |
| pubmed-article:8535642 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:8535642 | pubmed:articleTitle | Sulphasalazine, sulphapyridine or 5-aminosalicylic acid--which is the active moiety in rheumatoid arthritis? | lld:pubmed |
| pubmed-article:8535642 | pubmed:affiliation | Clinical Pharmacology Unit, Chapel Allerton Hospital, Leeds. | lld:pubmed |
| pubmed-article:8535642 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8535642 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8535642 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8535642 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8535642 | lld:pubmed |
